Hypocalcemia Management

Clinical Assessment and Diagnosis

The American College of Cardiology recommends examining patients with hypocalcemia for neuromuscular irritability signs, including Chvostek's and Trousseau's signs, paresthesias, tetany, seizures, bronchospasm, laryngospasm, and cardiac manifestations 1
Chvostek's sign is positive if facial muscle twitching occurs after tapping the facial nerve anterior to the ear 1, 2
Trousseau's sign is positive if carpopedal spasm develops after inflating a blood pressure cuff above systolic pressure for 3 minutes 1, 2
Patients with hypocalcemia should be assessed for neuromuscular symptoms, including muscle cramps, paresthesias, muscle weakness, and fatigue 3
Cardiac evaluation should include checking for prolonged QT interval on ECG, as hypocalcemia can cause cardiac arrhythmias and impair cardiac contractility 1, 3
Neurological assessment should evaluate for seizures, confusion, or altered mental status, particularly in severe cases 4

Measure pH-corrected ionized calcium, magnesium, parathyroid hormone (PTH), phosphorus, creatinine, and 25-hydroxyvitamin D levels to determine the etiology and severity of hypocalcemia 1, 3
Ionized calcium levels below 0.8 mmol/L require urgent correction due to cardiac dysrhythmia risk 1
Magnesium levels should be checked, as hypomagnesemia can impair PTH secretion and must be corrected for effective calcium management 3

For symptomatic patients or those with calcium below 7.5 mg/dL, administer calcium gluconate 50-100 mg/kg IV slowly with continuous ECG monitoring 1
Calcium gluconate is the preferred agent for IV administration, containing 90 mg elemental calcium per 10 mL of 10% solution 1
Calcium chloride may be preferable in liver dysfunction, containing 270 mg elemental calcium per 10 mL of 10% solution 1

Oral calcium carbonate supplementation (1-2 g three times daily) combined with vitamin D is the cornerstone of chronic management, with total elemental calcium intake not exceeding 2,000 mg/day 1, 2
Calcium carbonate is the preferred formulation, containing 40% elemental calcium, with initial dosing 1-2 g three times daily for severe hypocalcemia 1, 2
Vitamin D supplementation is recommended for patients with 25-hydroxyvitamin D levels below 30 ng/mL 1, 2

CKD patients (Stages 3-5) should maintain calcium in the normal range, preferably toward the lower end (8.4-9.5 mg/dL) in Stage 5 2
Patients with 22q11.2 deletion syndrome should receive daily calcium and vitamin D supplementation, as 80% have a lifetime history of hypocalcemia 3, 4

Check serum calcium and phosphorus every 3 months during chronic management, with more frequent monitoring (within 1 week) after treatment initiation or dose adjustments 1, 2
Target serum calcium levels should be in the low-normal range (8.4-9.5 mg/dL) to minimize hypercalciuria risk 2
Calcium-phosphorus product should be kept below 55 mg²/dL² 2

Over-correction of hypocalcemia can cause iatrogenic hypercalcemia, renal calculi, nephrocalcinosis, and renal failure 2, 3
Hypercalciuria should be monitored, particularly with combined calcium and vitamin D therapy, to prevent nephrocalcinosis 1
Patients should be counseled to avoid alcohol and carbonated beverages, which can worsen hypocalcemia 3